Teacher Retirement System of Texas Has $303,000 Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Teacher Retirement System of Texas grew its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) by 38.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,689 shares of the company’s stock after purchasing an additional 1,848 shares during the quarter. Teacher Retirement System of Texas’ holdings in Apogee Therapeutics were worth $303,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of APGE. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Apogee Therapeutics in the third quarter valued at about $71,000. Aigen Investment Management LP acquired a new stake in Apogee Therapeutics in the 4th quarter valued at about $216,000. Commonwealth Equity Services LLC bought a new position in shares of Apogee Therapeutics in the fourth quarter worth about $222,000. Wexford Capital LP acquired a new position in shares of Apogee Therapeutics during the third quarter worth approximately $230,000. Finally, Arizona State Retirement System grew its stake in shares of Apogee Therapeutics by 17.3% during the fourth quarter. Arizona State Retirement System now owns 6,517 shares of the company’s stock valued at $295,000 after purchasing an additional 960 shares during the last quarter. Institutional investors and hedge funds own 79.04% of the company’s stock.

Insider Buying and Selling at Apogee Therapeutics

In other news, insider Carl Dambkowski sold 3,520 shares of the business’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $40.69, for a total value of $143,228.80. Following the completion of the transaction, the insider now owns 252,623 shares of the company’s stock, valued at $10,279,229.87. The trade was a 1.37 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael Thomas Henderson sold 15,000 shares of the company’s stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $48.85, for a total transaction of $732,750.00. Following the completion of the sale, the chief executive officer now owns 1,309,487 shares of the company’s stock, valued at approximately $63,968,439.95. This represents a 1.13 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 49,195 shares of company stock valued at $2,026,392. 36.10% of the stock is currently owned by company insiders.

Apogee Therapeutics Stock Performance

Shares of APGE stock opened at $35.61 on Wednesday. The firm’s 50 day moving average price is $37.50 and its two-hundred day moving average price is $45.75. Apogee Therapeutics, Inc. has a 52-week low of $29.10 and a 52-week high of $66.80. The stock has a market cap of $1.60 billion, a PE ratio of -14.71 and a beta of 2.46.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.25). As a group, sell-side analysts predict that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on APGE. Wedbush restated an “outperform” rating and issued a $90.00 price objective on shares of Apogee Therapeutics in a research report on Tuesday, March 11th. Guggenheim restated a “buy” rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Finally, Citigroup assumed coverage on Apogee Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $95.00 price target on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $92.17.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.